USIBC concludes successful pharmaceutical mission to India

The US-India Business Council (USIBC) has concluded its Pharmaceutical Executive Mission to Delhi, India. The delegation expressed its commitment to the Indian market, called for further dialogue with the government on issues related to pricing and intellectual property, and discussed strategies for expanding greater access to health care and health insurance in India.

USIBC’s Executive Mission was led by Paul Schaper, executive director, global health policy, Merck & Co, and included senior representatives from Johnson & Johnson, Baxter, Mylan, Abbott, Eli Lilly, Watson and Quintiles.

During its visit, the Pharmaceutical Delegation met with the Ministry of Health, National Pharmaceutical Pricing Authority, Department of Industrial Policy and Promotion within the Ministry of Commerce and Industry, Drugs Controller General of India, Indian Institute of Corporate Affairs, and the Department of Biotechnology. The delegation also hosted briefings with the US Embassy, Confederation of Indian Industry, Khaitan & Co and representatives of the healthcare industry.